stockportfolio.pro
Abbott Laboratories (ABT)
Healthcare · Medical Devices · NYSE
Abbott Laboratories revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.85B | $27.39B | $30.58B | $31.90B | $34.61B | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| Gross profit | $11.76B | $14.98B | $17.87B | $18.67B | $19.61B | $24.54B | $24.51B | $22.13B | $23.24B | $25.01B |
| Net income | $1.40B | $477.00M | $2.37B | $3.69B | $4.50B | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B |
| Net margin | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
Source: Abbott Laboratories SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into ABT stock?
At today's market cap of $158.94B, Abbott Laboratories is priced for free-cash-flow growth of about 8.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $7.39B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 5.3%/yr over the last five fiscal years and revenue 5.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Abbott Laboratories financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ABT in your portfolio →
Abbott Laboratories financial history by metric
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Abbott Laboratories — frequently asked questions
What is Abbott Laboratories's revenue?
Abbott Laboratories (ABT) reported revenue of $44.33B for fiscal year 2025, up 5.7% from the prior year, according to its SEC filings.
Is Abbott Laboratories profitable?
Yes. ABT earned net income of $6.52B in fiscal 2025, a net margin of 14.7%.
What is ABT's P/E ratio?
Abbott Laboratories trades at a price-to-earnings ratio of about 25.3 based on the latest data in our nightly-refreshed cache.
How fast is Abbott Laboratories growing?
ABT's revenue grew at roughly 5.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Abbott Laboratories have?
As of fiscal year 2025, ABT carried roughly $12.93B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Abbott Laboratories's gross margin?
ABT's gross margin was 56.4% in fiscal 2025 — gross profit of $25.01B on revenue of $44.33B.
What is Abbott Laboratories's market cap?
Abbott Laboratories (ABT) has a market capitalization of about $158.94B, based on the latest data in our nightly-refreshed cache.
When does Abbott Laboratories's fiscal year end?
ABT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ABT stock?
At today's market cap of $158.94B, Abbott Laboratories is priced for free-cash-flow growth of about 8.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $7.39B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 5.3%/yr over the last five fiscal years and revenue 5.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Abbott Laboratories's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.